← All drugs Report issue

tas2940

Small moleculeexperimental

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

0

Phase 3

0

Phase 4

0

Earliest trial started Sep 16, 2021 (NCT04982926)

Timeline

2020s

Jan 1, 2021
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Receptor protein-tyrosine kinase erbB-4INHIBITOR
ERBB4 inhibitor
- Receptor tyrosine-protein kinase erbB-4 (ERBB4) ↗
Receptor protein-tyrosine kinase erbB-2INHIBITOR
ERBB2 inhibitor
- Receptor tyrosine-protein kinase erbB-2 (ERBB2) ↗
Epidermal growth factor receptor erbB1INHIBITOR
EGFR inhibitor
- Epidermal growth factor receptor (EGFR) ↗

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT04982926	Phase 1	Sep 16, 2021	Otsuka

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Otsuka	For profit	1	1	1	2021

1 organizations

Page 1 / 1